Eisai to double Belviq sales force by December
USA-based Arena Pharmaceuticals (Nasdaq: ARNA) says that partner Japanese drug major Eisai’s (TYO: 4523) US subsidiary will increase its force for the obesity drug Belviq (lorcaserin) to around 400 representatives by December 2013, doubling the size of the sales force from when Belviq became available in June 2013.
Belviq was approved by the US Food and Drug Administration more than a year ago, but had to await Drug Enforcement Administration (DEA) scheduling because of the drug’s abuse potential, which finally came through in the spring (The Pharma Letter May 8).
Follows increased health plans and PBMs coverage of the drug
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze